NCT04590625

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Apatinib Mesylate Combined With Albumin Binds Paclitaxel and Carboplatin or Cisplatinum as First-line Treatment for Stage II-IV Epithelial Ovarian Cancer Followed by Apatinib Maintenance Therapy:a Single-arm,Exploratory Clinical Study

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 58 (estimated)
• Sponsor: Zhongshan Hospital Xiamen University · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This monocentric, prospective, observational study will evaluate the safety and efficacy of apatinib in combination with albumin binds paclitaxel and carboplatin or cisplatinum as first-line treatment for stage II-IV epithelial ovarian cancer followed by apatinib maintenance therapy in routine clinical practice. Eligible patients will be followed for approximately 20 months.

Conditions

• Ovarian Cancer

Interventions

Type	Name	Description
DRUG	Apatinib Mesylate	apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd
DRUG	Abraxane	abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1
DRUG	Cis Platinum	cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1
DRUG	Carboplatin	carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1

Timeline

• Start date: 2020-10-01
• Primary completion: 2022-10-01
• Completion: 2023-12-01
• First posted: 2020-10-19
• Last updated: 2020-10-19

Locations

1 site across 1 country: China